Cadmium contributes to cardiac metabolic disruption by activating endothelial HIF1A-GLUT1 axis

Xiaoyu Zhang,Wendan Zheng,Shiyu Sun,Yang Du,Wenjuan Xu,Zongguo Sun,Fuhong Liu,Manzhi Wang,Zuohui Zhao,Ju Liu,Qiang Liu
DOI: https://doi.org/10.1016/j.cellsig.2024.111170
IF: 4.85
2024-04-12
Cellular Signalling
Abstract:Cadmium (Cd) is an environmental risk factor of cardiovascular diseases. Researchers have found that Cd exposure causes energy metabolic disorders in the heart decades ago. However, the underlying molecular mechanisms are still elusive. In this study, male C57BL/6 J mice were exposed to cadmium chloride (CdCl 2 ) through drinking water for 4 weeks. We found that exposure to CdCl 2 increased glucose uptake and utilization, and disrupted normal metabolisms in the heart. In vitro studies showed that CdCl 2 specifically increased endothelial glucose uptake without affecting cardiomyocytic glucose uptake and endothelial fatty acid uptake. The glucose transporter 1 (GLUT1) as well as its transcription factor HIF1A was significantly increased after CdCl 2 treatment in endothelial cells. Further investigations found that CdCl 2 treatment upregulated HIF1A expression by inhibiting its degradation through ubiquitin-proteasome pathway, thereby promoted its transcriptional activation of SLC2A1 . Administration of HIF1A small molecule inhibitor echinomycin and A-485 reversed CdCl 2 -mediated increase of glucose uptake in endothelial cells. In accordance with this, intravenous injection of echinomycin effectively ameliorated CdCl 2 -mediated metabolic disruptions in the heart. Our study uncovered the molecular mechanisms of Cd in contributing cardiac metabolic disruption by inhibiting HIF1A degradation and increasing GLUT1 transcriptional expression. Inhibition of HIF1A could be a potential strategy to ameliorate Cd-mediated cardiac metabolic disorders and Cd-related cardiovascular diseases.
cell biology
What problem does this paper attempt to address?